Moving candidate vaccines into development from research: lessons from HIV

Area of Science:

• Vaccinology
• Translational Medicine
• Biostatistics

Background:

• Vaccine development faces increasing cost and complexity from lab to clinic.
• Managing diverse, multidisciplinary teams requires specialized skills in communication and objective setting.

Purpose of the Study:

• To highlight the challenges in vaccine development, using HIV vaccinology as a case study.
• To propose practical steps for standardizing early vaccine evaluation to enhance efficiency.

Main Methods:

• Review of challenges in vaccine candidate selection and preclinical evaluation.
• Analysis of factors complicating interpretation of animal model data for human immunodeficiency virus (HIV) vaccines.
• Identification of barriers including lack of correlates of protection and high clinical trial costs.

Main Results:

• Early-stage vaccine development, particularly for HIV, is hindered by non-standardized animal models and complex variable analysis.
• Interpreting preclinical data is challenging, risking the advancement of poor candidates or elimination of viable ones.
• Lack of precise immunological correlates and expensive clinical trials pose significant hurdles.

Conclusions:

• Standardizing early vaccine evaluation is crucial for efficient development of vaccines for HIV and other complex diseases.
• Implementing rigorous scientific and statistical approaches improves candidate selection and regulatory compliance.
• Addressing challenges in preclinical evaluation can streamline the path to effective vaccines for diseases like hepatitis C virus, influenza, Mycobacterium tuberculosis, and malaria.